GLP-1 drugs are expensive, with list prices exceeding $1,000/month in many markets, and studies consistently show that people who stop taking semaglutide regain roughly two-thirds of the weight they lost, raising fundamental questions about whether these drugs represent treatment or lifelong pharmaceutical dependency
Pearson correlations were determined, and analysis of covariance (ANCOVA) models evaluated associations between PET findings and changes in weight
Over the last 10 years, prescribing GLP-1RAs has become increasingly prevalent due to their significant impact on diabetes disease control, weight loss, and cardiovascular disease risk reduction
Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer
Reporting even if you are uncertain whether the drug caused the symptom is an important contribution to drug safety monitoring